Pharmacokinetics Study of Gamma-aminobutyric Acid (GABA-PK)
The Pharmacokinetics of Gamma-aminobutyric Acid in Healthy Volunteers.
Panoramica dello studio
Stato
Descrizione dettagliata
Type 1 diabetes is an autoimmune disease resulting from the progressive loss of pancreatic insulin-secreting beta-cells. This consequently leads to a lack of insulin and elevation of blood sugar, namely hyperglycemia, which is a major cause for the development of diabetes and its acute or chronic complications. The current treatment for type 1 diabetes requires a life-long dependency on daily insulin injections, causing inconvenience and burden to patients. Drug-induced hypoglycemia is also common as it presents a major challenge in insulin therapy. Furthermore, although insulin therapy is lifesaving, it is not a cure as it neither reverses the progression of the disease nor prevents the development of serious complications associated with this disease. New treatments are urgently needed.
Recent studies have demonstrated that a natural chemical found in the brain, gamma-aminobutyric acid (GABA), which is also produced in large quantities by pancreatic beta-cells, has beta-cell regenerative and immunoregulatory effects. Importantly, GABA prevented and partially reversed diabetes in type 1 diabetes mouse models. It is important to address essential questions regarding the potential effects of GABA in diabetic patients in humans. Given the largely unknown mechanism of action of GABA in the pancreas, and the limited information on how GABA is absorbed, distributed and eliminated from the human body, we plan to examine these issues (referred to as pharmacokinetics/pharmacodynamics) in normal subjects.
The outcome of this study will provide useful information on the mechanism of action of GABA in human subjects.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Shanghai
-
Shanghai, Shanghai, Cina, 200040
- Department of Endocrinology and Metabolism，Huashan hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Volunteers in good health condition between 19 and 40 years of age (inclusive) at the time of signing the informed consent.
- Body mass index (BMI) between 18.5 and 24 kg/m2 (inclusive), with weight greater than 50 kg.
- Not on any medication 2 weeks before screening.
- No blood donation within 3 months before screening.
- Must sign the informed consent. Note: Blood and biochemical tests must be normal during the screening. However, if the participant's test-results were beyond the normal range, the individual can still be recruited as long as the results do not affect the experiment.
Exclusion Criteria:
- Abnormalities of physical examination, laboratory tests, or ECG in screening, which may influence the results of the study.
- Previous or existing history of severe heart, liver, kidney, gastrointestinal, nervous system, mental, or metabolic abnormalities as well as other diseases which can affect drug absorption, circulation, metabolism, or excretion.
- History of alcoholism, smoking, or drug abuse within the past 1 year.
- Participation in any clinical drug study within the past 30 days.
- Any definite or suspected allergy or family history of allergy to GABA or any other similar drugs.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
pharmacokinetic characteristics of γ-aminobutyric acid (GABA)
Lasso di tempo: baseline and up to 30 days
|
The primary endpoint of this study is to obtain the pharmacokinetic characteristics of γ-aminobutyric acid (GABA), including:
|
baseline and up to 30 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
serological characteristics
Lasso di tempo: baseline and up to 30 days
|
plasma glucose levels, insulin, C-peptide and glucagon levels will be measured
|
baseline and up to 30 days
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Exploratory measures
Lasso di tempo: baseline and up to 30 days
|
plasma glucagon-like peptide-1 (GLP-1) and glycated serum protein (GSP)will be measured.
|
baseline and up to 30 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Yiming Li, Huashan Hospital
- Investigatore principale: Qinghua Wang, Huashan Hospital/St Michael's Hospital
- Investigatore principale: Zheng Jiao, Huashan Hospital
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- KY-2013-222
- JDRF_17-2013-499 (Identificatore di registro: Juvenile Diabetes Research Foundation International (JDRF)])
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .